Clinical Trials Browser

Pancreatic Neoplasms × surufatinib × 30 days × Clear all

NCT07469956 2026-03-13

Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer

Phase 2 Not yet recruiting

Gastrointestinal

Pancreatic Neoplasms